For more information: www.cdc.gov/COVID19

ACIP COVID-19 Vaccines Work Group

Dr. Beth Bell, Work Group Chair

February 28, 2021
 COVID-19 Vaccine Work Group meets weekly 

 Topics covered:

–

–

–

–

–

Overview of Adenovirus vector vaccines

Clinical development program for Ad26.COV.2 (Janssen) COVID-19 vaccine

GRADE/EtR for Janssen COVID-19 vaccine

Considerations for the use of COVID-19 vaccines

Safety updates

COVID-19 Work Group activities – February 2021

2
 On February 27, 2021, the Food and Drug Administration (FDA) issued an 

Emergency Use Authorization (EUA) for use of the Janssen COVID-19 

vaccine for the prevention of Coronavirus Disease 2019 (COVID-19) for 

individuals 18 years of age and older

Update

3
 Overview of Janssen’s single dose COVID-19 vaccine, Ad26.COV2.S

Dr. Macaya Douoguih (Janssen Pharmaceuticals Companies of Johnson & Johnson)

 GRADE: Janssen COVID-19 vaccine

Dr. Julia Gargano (CDC)

 Evidence to Recommendation Framework: Janssen COVID-19 vaccine

Dr. Sara Oliver (CDC)

 Public Comment

 Discussion 

 VOTE: 

Janssen COVID-19 vaccine

Today's Agenda

Sunday, February 28
 Implementation considerations for COVID-19 vaccines

Dr. Kathleen Dooling (CDC)

 Clinical considerations for use of COVID-19 vaccines

Ms. Jessica MacNeil (CDC) 

 Vaccine Safety Technical Subgroup (VaST) introduction

Dr. Grace Lee (ACIP, VaST Co-chair)

 COVID-19 Vaccine Safety Update

Dr. Tom Shimabukuro (CDC)

 VaST assessment of safety data

Dr. Grace Lee (ACIP, VaST Co-chair)

 Emerging SARS-CoV-2 variants

Dr. Heather Scobie (CDC)

Tomorrow's Agenda

Monday, March 1
ACIP members

 Beth Bell (chair)

 Matthew Daley

 Grace Lee

 Jose Romero

 Keipp Talbot

Ex-officio/government members

 FDA: Doran Fink, Rachel Zhang

 NIH: Chris Roberts

 IHS: Thomas Weiser, Uzo Chukwuma

 DOD: Bryan Schumacher

 CMS: Jeff Kelman

 BARDA: Christine Oshansky

 HHS: David Kim

CDC Co-leads

 Kathleen Dooling

 Sara Oliver

Work group members

6

Liaisons

 AAFP: Jonathan Temte

 AAP: Sean O’Leary

 ACOG: Denise Jamieson (primary), 

Laura Riley (alternate)

 ACP: Jason Goldman

 AGS: Ken Schmader

 AIM: Rob Shechter (primary), 

Jane Zucker (alternate)

 AMA: Sandra Fryhofer

 ANA: Kendra McMillan (primary), 

Ruth Francis (alternate)

 APhA: Michael Hogue

 ASTHO: Marcus Plescia

 CSTE: Susan Lett (primary), 

Christine Hahn (alternate)

 IDSA: Jeff Duchin (primary), 

Carol Baker (alternate)

Liaisons, cont’d

 NACCHO: Matt Zahn (primary), 

Jeff Duchin (alternate)

 NACI: Matthew Tunis 

 NFID: Bill Schaffner (primary), 

Marla Dalton (alternate)

 NMA: Oliver Brooks

 SHEA: Marci Drees

Consultants

 Ed Belongia

 Kathy Kinlaw 

 Dayna Matthew 

 Kathleen Neuzil 

 Stanley Perlman 

 Peter Szilagyi
 Amy Blaine

 Doug Campos-Outcalt

 Mary Chamberland

 Thomas Clark

 Amanda Cohn

 Jean Cox-Ganser

 Jonathan Duffy

 Anthony Fiore

 Mark Freedman

 Sue Gerber

 Jack Gersten

 Susan Goldstein

 Sam Graitcer

 Lisa Grohskopf

 Julie Garon

CDC participants

7

 Stephen Hadler

 Rita Helfand

 Susan Hiers

 Terri Hyde

 Cynthia Jorgensen

 Erin Kennedy

 Sarah Kidd

 Ram Koppaka

 Nicole Lindsey

 Ruth Link-Gelles

 Jessica MacNeil

 Lauri Markowitz

 Mona Marin

 Sarah Mbaeyi

 Nancy Messonnier

 Cindy Weinbaum

 Melinda Wharton

 Yon Yu

 Rebecca Morgan

 Titilope Oduyebo

 Anita Patel

 Janell Routh

 Stephanie Schrag

 Heather Scobie

 Edwin Shanley

 Tom Shimabukuro

 Heidi Soeters

 Mark Sotir

 Stephanie Thomas

 Natalie Thornburg

 Jennifer Verani

 Megan Wallace

 Annemarie Wasley
For more information, contact CDC

1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the 

official position of the Centers for Disease Control and Prevention.

Thank you!